TipRanks
Advertisement
Advertisement

DRUG Stock Latest News

Bright Minds Deepens Prader-Willi Focus as BMB-101 Advances in Phase 2 Trial
Company AnnouncementsBright Minds Deepens Prader-Willi Focus as BMB-101 Advances in Phase 2 Trial
38s ago
DRUG
Bright Minds initiated with an Outperform at LifeSci Capital
PremiumThe Fly
Bright Minds initiated with an Outperform at LifeSci Capital
2d ago
DRUG
Analyst Reiterates Buy on Bright Minds Biosciences, Citing Differentiated 5-HT2C Epilepsy Asset and Multibillion-Dollar Upside vs. Current Valuation
PremiumRatings
Analyst Reiterates Buy on Bright Minds Biosciences, Citing Differentiated 5-HT2C Epilepsy Asset and Multibillion-Dollar Upside vs. Current Valuation
2d ago
DRUG
Psychedelic: Enveric, Helus, Bright Minds report earnings results
PremiumThe Fly
Psychedelic: Enveric, Helus, Bright Minds report earnings results
1M ago
LLY
ATAI
Bright Minds Biosciences: Buy Rating Reaffirmed with Unchanged $145 Target on BMB-101 Phase 3 Pathway and Pipeline Upside
PremiumRatings
Bright Minds Biosciences: Buy Rating Reaffirmed with Unchanged $145 Target on BMB-101 Phase 3 Pathway and Pipeline Upside
1M ago
DRUG
Bright Minds Biosciences Inc. (DRUG) Q3 Earnings Cheat Sheet
PremiumPre-EarningsBright Minds Biosciences Inc. (DRUG) Q3 Earnings Cheat Sheet
2M ago
DRUG
One new option listing on July 7th
Premium
The Fly
One new option listing on July 7th
3M ago
DRUG
Bright Minds Biosciences Sets March 31, 2026 AGM, Files Meeting Materials on Form 6-K
Premium
Company Announcements
Bright Minds Biosciences Sets March 31, 2026 AGM, Files Meeting Materials on Form 6-K
4M ago
6K
DRUG
Bright Minds Biosciences Sets March 31, 2026 Date for Annual General Meeting
PremiumCompany Announcements
Bright Minds Biosciences Sets March 31, 2026 Date for Annual General Meeting
4M ago
6K
DRUG
Buy Rating Reiterated on Bright Minds Biosciences as BMB-101 De-Risking Progresses; $145 Price Target Maintained
PremiumRatings
Buy Rating Reiterated on Bright Minds Biosciences as BMB-101 De-Risking Progresses; $145 Price Target Maintained
4M ago
DRUG
Bright Minds Biosciences to Present at Jefferies Healthcare Conference and Grants New Stock Options
PremiumCompany Announcements
Bright Minds Biosciences to Present at Jefferies Healthcare Conference and Grants New Stock Options
4M ago
6K
DRUG
Psychedelic: Enveric, NRx, Bright Minds report quarterly earnings
PremiumThe Fly
Psychedelic: Enveric, NRx, Bright Minds report quarterly earnings
4M ago
CMND
CMPS
Bright Minds Biosciences Boosts Cash Reserves as R&D Losses Widen in Q2 2026 Filing
PremiumCompany AnnouncementsBright Minds Biosciences Boosts Cash Reserves as R&D Losses Widen in Q2 2026 Filing
4M ago
6K
DRUG
Bright Minds price target raised to $220 from $190 at Piper Sandler
Premium
The Fly
Bright Minds price target raised to $220 from $190 at Piper Sandler
4M ago
DRUG
Is DRUG a Buy, Before Earnings?
Premium
Pre-Earnings
Is DRUG a Buy, Before Earnings?
5M ago
DRUG
Psychedelic: Clearmind’s CMND-100 meets primary endpoint in trial
PremiumThe Fly
Psychedelic: Clearmind’s CMND-100 meets primary endpoint in trial
6M ago
BMY
CMND
Bright Minds initiated with a Buy at Jefferies
PremiumThe Fly
Bright Minds initiated with a Buy at Jefferies
6M ago
DRUG
Buy Rating on BMB-101 Driven by Strong Phase 2 Epilepsy Data, Differentiated Safety, and Prader–Willi Upside Supporting DCF Valuation
PremiumRatings
Buy Rating on BMB-101 Driven by Strong Phase 2 Epilepsy Data, Differentiated Safety, and Prader–Willi Upside Supporting DCF Valuation
6M ago
DRUG
Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results
PremiumThe Fly
Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results
7M ago
PBM
ATAI
Bright Minds price target raised to $145 from $115 at H.C. Wainwright
PremiumThe FlyBright Minds price target raised to $145 from $115 at H.C. Wainwright
7M ago
DRUG
Compelling Phase 2 Data and Prader–Willi Upside Support Buy Rating and Favorable Risk/Reward for DRUG
Premium
Ratings
Compelling Phase 2 Data and Prader–Willi Upside Support Buy Rating and Favorable Risk/Reward for DRUG
8M ago
DRUG
De-Risked Neurology Pipeline and Pivotal 2026 Catalysts Underpin Buy Rating on BMB-101 Franchise
Premium
Ratings
De-Risked Neurology Pipeline and Pivotal 2026 Catalysts Underpin Buy Rating on BMB-101 Franchise
8M ago
DRUG

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >